Shire PLC (SHPGY)
Symbol Info
Listed Symbol SHPGY
Name Shire PLC
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2017-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $
Price Info
21 Day Moving Average $-
21 Day EMA $-
50 Day Moving Average $-
50 Day EMA $-
200 Day EMA $-
200 Day Moving Average -
52 Week High $
52 Week Low $-
52 Week Change $
Alpha
Beta
Standard Deviation
R2
Periods
Share Information
10 Day Average Volume -
20 Day Average Volume -
30 Day Average Volume -
50 Day Average Volume -
Outstanding Shares 306,040,132
Float Shares 305,653,577
Percent Float 99.87%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1,020
Institute Holdings Date 2018-12-31
Institute Bought Previous 3 Months 9,575,647
Institute Holdings Percent 24.600000
Institute Sold Previous 3 Months 12,471,834
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 386,555
Price Change
7 Day Price Change $-
7 Day Percent Change -
21 Day Price Change $-
21 Day Percent Change -
30 Day Price Change $-
30 Day Percent Change -
Month To Date Price Change $-
Month To Date Percent -
90 Day Price Change $-
90 Day Percent Change -
Quarter To Date $-
Quarter To Date Percent -
180 Day Price Change $-
180 Day Percent Change -
200 Day Price Change $-
200 Day Percent Change -
Year To Date $-
Year To Date Percent -
Profile
Description Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Details
Issue Type CS
Market Cap $-
Sec Type DR
Auditor
Total Shares Outstanding -
CEO Flemming Ornskov
Employees 23,044
Last Audit
Classification
CIK 0000936402
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 50-58 Baggot Street Lower
Block 2, Miesian Plaza
Dublin, 2
Website http://www.shire.com
Facisimile
Telephone +353 16096000
Email investorrelations@shire.com
Key Ratios
Profitability
EBIT Margin 21.00
EBITDA Margin 36.5
Pre-Tax Profit Margin 21.2
Profit Margin Cont 14.74
Gross Margin 70.30
Profit Margin TOT 14.74
Income Statements
Revenue $-
Revenue Per Share $2,898.1360
Revenue 3 Years $29.10
Revenue 5 Years $30.44
Valuation Measures
PE Ratio 11.40
Enterprise Value $-
Price To Sales -
Price To Free Cash 12.800000
PE High Last 5 Years 100.1
Price To Book 1.5
Price To Cash Flow 12.6
PE Low Last 5 Years 10.7
Price To Tangible Book -4.8
Financial Strength
Total Debt To Equity 0.4
Int Coverage 6.2
Current Ratio 0.9
Leverage Ratio 1.8
Quick Ratio -
Long Term Debt To Capital 0.23
Assets
Receivables Turnover -
Invoice Turnover 1.40
Assets Turnover 0.20
Management Effectiveness
Return Assets 7.37
Return On Equity 13.82
Return On Capital 9.80
Dividends
Dividend 3 Years $13.39
Dividend 5 Years $14.11
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SHPGY
Shire
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.